Results 1 to 10 of about 1,615,709 (243)

RAMIPRIL IN THERAPY OF PATIENTS AFTER MYOCARDIAL INFARCTION

Рациональная фармакотерапия в кардиологии, 2015
Angiotensin converting enzyme inhibitors are the first line medicine for the treatment of the most of cardiovascular diseases. There is no class-effect for these drugs in myocardial infarction therapy.
I. V. Szirov, E. V. Malichenko
doaj   +3 more sources

Acute Kidney Injury in a Case Series of Patients with Confirmed COVID-19 (Coronavirus Disease 2019): Role of Angiotensin-Converting Enzyme 2 and Renin-Angiotensin System Blockade

Case Reports in Nephrology, 2020
The renin-angiotensin system plays a very critical role in hypertension, diabetes, and kidney and heart diseases. The blockade of the renin-angiotensin system results in the prevention of progression of renal and cardiac damage.
Avantika Chenna, Venu Madhav Konala, Subhasish Bose, Sasmit Roy, Bhaskar Reddy Madhira, Vijay Gayam, Srikanth Naramala, Sreedhar Adapa   +7 more
doaj   +1 more source

Comparison of Pharmacy Refill Data With Chemical Adherence Testing in Assessing Medication Nonadherence in a Safety Net Hospital Setting

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022
Background Pharmacy fill data are a practical tool for assessing medication nonadherence. However, previous studies have not compared the accuracy of pharmacy fill data to measurement of plasma drug levels, or chemical adherence testing (CAT).
David Osula, Bryan Wu, Kevin Schesing, Sandeep R. Das, Elizabeth Moss, Kristin Alvarez, Christopher Clark, Ethan A. Halm, Nancy J Brown, Wanpen Vongpatanasin   +9 more
doaj   +1 more source

Why not change the therapy of hypertension in patients with COVID-19. Dual role of angiotensin-converting enzyme 2

Arterial Hypertension, 2022
Despite many organizational and medical efforts, the COVID-19 epidemic continues and is taking a lethal toll. Preliminary reports have already reported that the mortality associated with this disease is much higher in people with comorbidities, including
Jerzy Głuszek, Teresa Kosicka
doaj   +1 more source

Angiotensin II and COVID-19. Secrets of interactions

Российский кардиологический журнал, 2020
The article describes current data on the relationship of renin-angiotensin system and related drugs with the risk of COVID-19 infection and its outcomes.
A. O. Konradi, A. O. Nedoshivin
doaj   +1 more source

Small molecule angiotensin converting enzyme inhibitors: A medicinal chemistry perspective

Frontiers in Pharmacology, 2022
Angiotensin-converting enzyme (ACE), a zinc metalloprotein, is a central component of the renin–angiotensin system (RAS). It degrades bradykinin and other vasoactive peptides.
Wenyue Zheng, Wenyue Zheng, Erkang Tian, Zhen Liu, Changhan Zhou, Pei Yang, Pei Yang, Keyue Tian, Wen Liao, Juan Li, Changyu Ren   +10 more
doaj   +1 more source

Renin–Angiotensin–Aldosterone System Inhibitors in Patients with COVID-19: General Considerations and Clinical Implications

Journal of Cardiac Arrhythmias, 2020
Initially reported in China at the end of 2019, the coronavirus pandemic has now reached an international scale with more than1.5 million cases worldwide and more than 80,000 deaths by April 8th of this year.
Neiberg de Alcantara Lima, Pedro Yuri Paiva Lima, Ricardo Lessa de Castro Junior, Eric Martin Sieloff, Stela Maria Vitorino Sampaio   +4 more
doaj   +1 more source

Angiotensin-converting Enzyme Inhibitors-induced Angioedema

Journal of Cardiovascular Emergencies, 2018
Angiotensin-converting enzyme inhibitors (ACEI) are widely used drugs nowadays in treating patients diagnosed with cardiovascular disorders. We present two consecutive cases of acquired angioedema caused by the administration of enalapril and lisinopril ...
Chiriac Anca, Brzezinski Piotr, Betiu Mircea, Foia Liliana   +3 more
doaj   +1 more source

The use of angiotensin-converting enzyme inhibitors in general medicine

South African Family Practice, 2012
Angiotensin-converting enzyme (ACE) inhibitors are a class of drugs commonly used in the management of hypertension, congestive heart failure, cerebrovascular disease, stable coronary heart disease and diabetes-associated nephropathy.
M.L.I. Mashitisho
doaj   +1 more source

SGLT2 Inhibitors for Nephrologists

European Medical Journal Nephrology, 2022
Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are the mainstay of therapy for the prevention of progressive renal damage in diabetic and non-diabetic kidney diseases, especially glomerulonephritides.
Mufti Baleegh-ur-Raheem Mahmood, Sidra Farishta   +1 more
doaj   +1 more source